Adnkronos Rome, October 13 (Adnkronos Salute) – "Preclinical, clinical, and real-world research is the true value of a pharmaceutical company. Conducting research is important for ensuring the availability of innovative drugs before they are released to the market. These resources also have positive effects on the national healthcare system." This was stated by Francesca Patarnello, Vice President of Market Access & Government Affairs at AstraZeneca Italy, speaking in Milan at the first meeting of the format dedicated to major healthcare issues, 'AstraZeneca Agorà'.
For Patarnello, "all research is good," whether "independent or not," but "it must be conducted appropriately, perfectly consistent with rules and regulations. It is important to protect the research ecosystem and ensure that citizens and stakeholders understand it." "Participation in research improves healthcare, generates knowledge, networks, and collaborations," Patarnello emphasizes, "even if its effects are only noticeable after 10-15 years."
AstraZeneca ranks first in Italy in terms of the number of clinical trials – according to a statement. The pharmaceutical company has allocated nearly €100 million to Research and Development in the two-year period 2023-24, and in 2023 it managed nearly 200 active clinical trials at 621 centers in 17 Italian regions, confirming its widespread presence. There are 19 new molecules in the final stages of development that hold the promise of innovative therapies for Italian patients. In this sense, our country is fertile ground. This is due to the "quality of its researchers and the excellence in the supply chain. Compared to other countries, there are many good reasons to invest in research in Italy," he concludes.